Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Council Recommends Switching of 4 APIs; Switching of Levonorgestrel for Emergency Contraception Disapproved
The Ministry of Health, Labor and Welfare’s (MHLW) council on the switching from prescription to nonprescription drugs discussed on July 26 whether five ethical APIs might be switched to OTC status in response to requests from related medical societies and…
To read the full story
Related Article
- Japan’s 1st OTC Morning-After Pill Now Available
February 3, 2026
- Daiichi Sankyo Unveils Brand Site for OTC NorLevo Ahead of Launch
January 15, 2026
- Daiichi Sets February Launch for Japan’s 1st OTC Morning-After Pill
December 19, 2025
- Japan Approves Nonprescription Version of Morning-After Pill: ASKA
October 21, 2025
- Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
- Japan Moves Toward OTC Morning-After Pill Sales Without Age Limit or Parental Consent
August 29, 2025
- Set Deadline for Non-Prescription Pilot of Morning-After Pill: Panel Members
February 13, 2025
- Purchasers Satisfied, Pharmacy Service “Appropriate” in Non-Prescription Pilot for Emergency Contraceptives
May 14, 2024
- MHLW to Run Pilot Sale of Emergency Contraceptives without Prescription
June 29, 2023
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- MHLW Mulls New OTC Class to Bar Online Sales amid Unease over Morning After Pills
June 14, 2023
- LDP Lawmakers Oppose Online Sale of Morning After Pills 3 Years after Switch
June 8, 2023
- MHLW Taking Public Comments on OTC Access to Emergency Contraceptives
January 6, 2023
- 6 APIs Added to List of “Switch OTC” Candidates: MHLW
June 26, 2017
- MHLW Announces 16 APIs as Candidates for Switch-OTC Status: None for Lifestyle Diseases
December 13, 2016
- New Scheme on Switch OTC Gets Underway
April 14, 2016
REGULATORY
- Japan Panel Backs Daiichi’s MMR Vaccine, Haihe’s PI3Kα Inhibitor, MSD’s HIV Med
March 3, 2026
- MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act
March 3, 2026
- MHLW Details New Operational Rules for Conditional Approvals from May
March 3, 2026
- MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
March 2, 2026
- WG Members Urge Domestic Biologic Production as National Growth Strategy
March 2, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…